Related Experiment Video

Updated: Jul 12, 2026

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method
16:07

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method

Published on: September 16, 2017

Synthesis of 3-O-methylviridicatin analogues with improved anti-TNF-alpha properties

Nigel Ribeiro1, Helena Tabaka, Jean Peluso

  • 1UMR 7175 LC1, ULP-CNRS, Faculté de Pharmacie, 67401 Illkirch, France.

Bioorganic & Medicinal Chemistry Letters
|September 5, 2007
PubMed

Insights

Researchers synthesized fungal metabolites, finding that replacing a methoxy group with thiomethyl significantly boosted inhibition of tumor necrosis factor-alpha (TNF-alpha) secretion, suggesting potential anti-inflammatory agents.

Area of Science:

  • Medicinal Chemistry
  • Pharmacology
  • Natural Products

Background:

  • Tumor necrosis factor-alpha (TNF-alpha) is a key mediator of inflammation.
  • Fungal metabolites represent a rich source of novel therapeutic compounds.
  • Viridicatin analogues have shown potential biological activities.

Purpose of the Study:

  • To synthesize 3-O-methylviridicatin and novel analogues.
  • To evaluate the impact of structural modifications on TNF-alpha inhibitory activity.
  • To explore the potential of these compounds as anti-inflammatory agents.

Main Methods:

  • Chemical synthesis of 3-O-methylviridicatin and analogues.
  • In vitro assays to measure TNF-alpha secretion inhibition.
  • Structure-activity relationship analysis.

Main Results:

  • Synthesis of target compounds was successful.
  • Replacement of the methoxy moiety with a thiomethyl group markedly enhanced TNF-alpha inhibition.
  • 4-phenyl-3-methylthioquinolinone demonstrated potent anti-inflammatory properties.

Conclusions:

  • Structural modification of fungal metabolites can lead to enhanced biological activity.
  • 4-phenyl-3-methylthioquinolinone is a promising lead compound for developing new anti-inflammatory drugs.
  • Targeting TNF-alpha secretion is a viable strategy for inflammation management.

More Related Videos

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Synthesis and Bioconjugation of Thiol-Reactive Reagents for the Creation of Site-Selectively Modified Immunoconjugates08:47

Synthesis and Bioconjugation of Thiol-Reactive Reagents for the Creation of Site-Selectively Modified Immunoconjugates

Published on: March 6, 2019

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...